Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3830891 | 0.99 | HTR4 (0.42) | HTR4OGACNR2CNR1GRM5 | |
| SCHEMBL2893441 | 0.83 | CNR1 (0.48) | HTR4OGACNR2CNR1GRM5 | |
| Hydrochloric Acid SCHEMBL3833783 | 0.82 | CNR1 (0.47) | HTR4OGACNR2CNR1GRM5 | |
| SCHEMBL15312791 | 0.76 | GRM5 (0.45) | OGACNR2CNR1GRM5USP30 | |
| SCHEMBL2894125 | 0.74 | HTR4 (0.49) | HTR4OGAPLATPOLB | |
| SCHEMBL10057663 | 0.74 | OGA (0.57) | HTR4OGATLR9TLR8TLR7 | |
| SCHEMBL19450546 | 0.74 | USP7 (0.52) | CNR2CNR1GRM5USP30GPR119 | |
| Hydrochloric Acid SCHEMBL3831561 | 0.73 | HTR4 (0.48) | HTR4OGAPLATPOLB | |
| SCHEMBL12026465 | 0.73 | CNR2 (0.51) | HTR4OGACNR2KCNH2GPR119 | |
| SCHEMBL12026464 | 0.71 | HTR4 (0.46) | HTR4OGACNR2GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585515-B1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-09-16 | — | — | EP | claimed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799924-B2 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1585515-B1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | VTVX HOLDINGS II LLC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH3, HRH4, HRH2 | HTR4 13/4885OGA 4278/4885CNR2 43/4885 |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH4, HRH3, HRH2 | HTR4 10/4885OGA 3978/4885CNR2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.